NORWICH – Norwich Pharmaceuticals Inc., a leader in full-service contract development and manufacturing, is expanding its services to now include small scale feasibility and initial product development for prescription and over-the-counter pharmaceuticals. The non-GMP development facility will offer Norwich customers greater flexibility and speed when assessing the feasibility of technical concepts and formulations, and create streamlined progression from clinical into scale-up and through commercial manufacturing.
Norwich’s comprehensive product development capabilities include formulation, analytical method development and validation, process optimization, and scalable manufacturing. The state-of-the-art, non-GMP facility is comprised of an analytical laboratory designed for potent compound handling, and a development area enabling formulation and product transfer verification. The company also has a pilot plant for technology transfer and small-scale manufacturing.
“Establishing feasibility and initial product development capabilities fills a significant unmet need for customers who are seeking a complete range of services from a contract provider. It also underscores our focus to build a robust capability for all stages of the product lifecycle,” said Chris Calhoun, president of Norwich Pharmaceuticals.